Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Rezaltas No. 1 in Both HP, GP Market
June 21, 2010
- Korosho to Consult Medical Societies on 19 Switch OTC Drug Candidates
June 21, 2010
- GenomIdea Receives Grant for Developing DNA Vaccines for Pandemic Flu
June 21, 2010
- Eisai Licenses Netupitant + Palonosetron Combinations from Helsinn in US
June 21, 2010
- Pfizer Oncology to Accelerate Multinational Trials to Eliminate “Drug Lag” VP S. Lowenthal
June 21, 2010
- Risk of Stroke Reduced by Intensified Intervention in Japanese Diabetes Patients
June 21, 2010
- Ranbaxy Launches Prasugrel in India
June 21, 2010
- Roche Aims to Apply for 5 Anticancer Agents by 2013: VP Hal Barron
June 21, 2010
- Radiotherapy May Be Omitted in Elderly Breast Cancer Patients
June 21, 2010
- High % of Prescriptions Still Prohibit Generic Substitution: Nihon Chouzai
June 21, 2010
- Merck Serono to Accelerate Development of Personalized Cancer Treatments: EVP W. Wein
June 21, 2010
- ROCA Screening Useful for Early Detection of Ovarian Cancer
June 21, 2010
- Combined Sales of Top-4 Generic-Only Makers Up 15.5%
June 21, 2010
- ASCO 2010 in Chicago (1)
June 21, 2010
- Over 60% of Local Gov't Hospitals Running at a Loss
June 21, 2010
- JGA's Generics Information Supply System Gets on Track
June 21, 2010
- Eribulin Prolongs OS but Not PFS
June 21, 2010
- Leptin Replacement Therapy for Lipoatrophy Recommended as Advanced Therapy
June 21, 2010
- 635 MSs to Take 1 Exam for Certification
June 21, 2010
- Eribulin Shows High ORR in Japanese Patients
June 21, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…